Candidate vaccines for human Rift Valley fever

References

• Linthicum KJ, Davies FG, Kairo A, et al. Rift Valley fever virus (family Bunyaviridae, genus Phlebovirus). Isolations from diptera collected during an inter-epizootic period in Kenya. J Hyg. 1985;95:197–209.
   PubMedGoogle Scholar
• Linthicum KJ, Britch SC, Anyamba A. Rift Valley fever: an emerging mosquito-borne disease. Annu Rev Entomol. 2016;61:395–415.
   PubMed Web of Science ®Google Scholar
• Njenga MK, Bett B. Rift Valley fever virus - how and where virus is maintained during inter-epidemic periods. Curr Clin Microbiol Rep. 2019;6:18–24.
   Web of Science ®Google Scholar
• Daubney R, Hudson JR. Enzootic hepatitis or Rift Valley fever: an undescribed virus disease of sheep cattle and man from east Africa. J Pathol Bacteriol. 1931;34:545–579.
   Google Scholar
• Dar O, McIntyre S, Hogarth S, et al. Rift Valley fever and a new paradigm of research and development for zoonotic disease control. Emerg Infect Dis. 2013;19:189–193.
   PubMed Web of Science ®Google Scholar
• McMillen CM, Hartman AL. Rift Valley fever in animals and humans: current perspectives. Antiviral Res. 2018;156:29–37.
   PubMed Web of Science ®Google Scholar
• Owino EA. Enhanced surveillance and cohesive policies needed to tackle Rift Valley fever. Asian Pac J Trop Med. 2018;11:547–548.
   Web of Science ®Google Scholar
• Peyre M, Chevalier V, Abdo-Salem S, et al. A systematic scoping study of the socio-economic impact of Rift Valley fever: research gaps and needs. Zoonoses Public Health. 2015;62:309–325.
   PubMed Web of Science ®Google Scholar
• Swanepoel R, Coetzer JAW. Rift Valley fever. In: Coetzer JAW, Tustin RC, editors. Infectious diseases of livestock with special reference to southern Africa. 2nd ed. Cape Town, South Africa: Oxford University Press; 2004. p. 1037–1070.
   Google Scholar
• Arishi HM, Aqeel AY, Al Hazmi MM. Vertical transmission of fatal Rift Valley fever in a newborn. Ann Trop Paediatr. 2006;26:251–253.
   PubMed Web of Science ®Google Scholar
• Adam I, Karsany MS. Case report: Rift Valley fever with vertical transmission in a pregnant Sudanese woman. J Med Virol. 2008;80:929.
   PubMed Web of Science ®Google Scholar
• van Velden DJ, Meyer JD, Olivier J, et al. Rift Valley fever affecting humans in South Africa: a clinicopathological study. S Afr Med J. 1977;51:867–871.
   PubMed Web of Science ®Google Scholar
• Ikegami T, Makino S. The pathogenesis of Rift Valley fever. Viruses. 2011;3:493–519.
   PubMed Web of Science ®Google Scholar
• Dungu B, Lubisi BA, Ikegami T. Rift Valley fever vaccines: current and future needs. Curr Opin Virol. 2018;29:8–15.
   PubMed Web of Science ®Google Scholar
• Randall R, Binn LN, Harrison VR. Immunization against Rift Valley fever virus. Studies on the immunogenicity of lyophilized formalin-inactivated vaccine. J Immunol. 1964;93:293–299.
   PubMed Web of Science ®Google Scholar
• Randall R, Gibbs CJ Jr., Aulisio CG, et al. The development of a formalin-killed Rift Valley fever virus vaccine for use in man. J Immunol. 1962;89:660–671.
   PubMedGoogle Scholar
• Randall R, Binn LN, Harrison VR. Rift Valley fever virus vaccine. Am J Trop Med Hyg. 1963;12:611–615.
   Web of Science ®Google Scholar
• Eddy GA, Peters CJ, Meadors G, et al. Rift Valley fever vaccine for humans. Contr Epidem Biostatist. 1981;3:124–141.
   Google Scholar
• Kark JD, Aynor Y, Peters CJ. A Rift Valley fever vaccine trial. I. Side effects and serologic response over a six-month follow-up. Am J Epidemiol. 1982;116:808–820.
   PubMed Web of Science ®Google Scholar
• Meegan JM, Niklasson B, Bengtsson E. Spread of Rift Valley fever virus from continental Africa. Lancet. 1979;2:1184–1185.
   PubMed Web of Science ®Google Scholar
• Niklasson B. Rift Valley fever virus vaccine trial: study of side-effects in humans. Scand J Infect Dis. 1982;14:105–109.
   PubMed Web of Science ®Google Scholar
• Niklasson B, Peters CJ, Bengtsson E, et al. Rift Valley fever virus vaccine trial: study of neutralizing antibody response in humans. Vaccine. 1985;3:123–127.
   PubMed Web of Science ®Google Scholar
• Kark JD, Aynor Y, Peters CJ. A Rift Valley fever vaccine trial: 2. Serological response to booster doses with a comparison of intradermal versus subcutaneous injection. Vaccine. 1985;3:117–122.
   PubMed Web of Science ®Google Scholar
• Meadors GF 3rd, Gibbs PH, Peters CJ. Evaluation of a new Rift Valley fever vaccine: safety and immunogenicity trials. Vaccine. 1986;4:179–184.
   PubMed Web of Science ®Google Scholar
• Rusnak JM, Gibbs P, Boudreau E, et al. Immunogenicity and safety of an inactivated Rift Valley fever vaccine in a 19-year study. Vaccine. 2011;29:3222–3229.
   PubMed Web of Science ®Google Scholar
• Caplen H, Peters CJ, Bishop DH. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J Gen Virol. 1985;66:2271–2277.
   PubMed Web of Science ®Google Scholar
• Ikegami T. Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate. Expert Rev Vaccines. 2017;16:601–611.
   PubMed Web of Science ®Google Scholar
• Ikegami T, Hill TE, Smith JK, et al. Rift Valley fever virus MP-12 vaccine is fully attenuated by a combination of partial attenuations in the S, M, and L segments. J Virol. 2015;89:7262–7276.
   PubMed Web of Science ®Google Scholar
• Saluzzo JF, Smith JF. Use of reassortant viruses to map attenuating and temperature-sensitive mutations of the Rift Valley fever virus MP-12 vaccine. Vaccine. 1990;8:369–375.
   PubMed Web of Science ®Google Scholar
• Nishiyama S, Lokugamage N, Ikegami T, et al. M- and S-segments of Rift Valley fever virus MP-12 vaccine independently contribute to a temperature-sensitive phenotype. J Virol. 2016;90:3735–37644.
   PubMed Web of Science ®Google Scholar
• Baskerville A, Hubbard KA, Stephenson JR. Comparison of the pathogenicity for pregnant sheep of Rift Valley fever virus and a live attenuated vaccine. Res Vet Sci. 1992;52:307–311.
   PubMed Web of Science ®Google Scholar
• Hubbard KA, Baskerville A, Stephenson JR. Ability of a mutagenized virus variant to protect young lambs from Rift Valley fever. Am J Vet Res. 1991;52:50–55.
   PubMed Web of Science ®Google Scholar
• Morrill JC, Carpenter L, Taylor D, et al. Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep. Vaccine. 1991;9:35–41.
   PubMed Web of Science ®Google Scholar
• Morrill JC, Jennings GB, Caplen H, et al. Pathogenicity and immunogenicity of a mutagen-attenuated Rift Valley fever virus immunogen in pregnant ewes. Am J Vet Res. 1987;48:1042–1047.
   PubMed Web of Science ®Google Scholar
• Morrill JC, Mebus CA, Peters CJ. Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids. Am J Vet Res. 1997;58:1110–1114.
   PubMed Web of Science ®Google Scholar
• Morrill JC, Mebus CA, Peters CJ. Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle. Am J Vet Res. 1997;58:1104–1109.
   PubMed Web of Science ®Google Scholar
• Morrill JC, Peters CJ. Pathogenicity and neurovirulence of a mutagen-attenuated Rift Valley fever vaccine in rhesus monkeys. Vaccine. 2003;21:2994–3002.
   PubMed Web of Science ®Google Scholar
• Wilson WC, Bawa B, Drolet BS, et al. Evaluation of lamb and calf responses to Rift Valley fever MP-12 vaccination. Vet Microbiol. 2014;172:44–50.
   PubMed Web of Science ®Google Scholar
• Morrill JC, Laughlin RC, Lokugamage N, et al. Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep. Vaccine. 2013;31:559–565.
   PubMed Web of Science ®Google Scholar
• Hunter P, Erasmus BJ, Vorster JH. Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep. Onderstepoort J Vet Res. 2002;69:95–98.
   PubMed Web of Science ®Google Scholar
• Miller MM, Bennett KE, Drolet BS, et al. Evaluation of the efficacy, potential for vector transmission, and duration of immunity of MP-12, an attenuated Rift Valley fever virus vaccine candidate, in sheep. Clin Vaccine Immunol. 2015;22:930–937.
   PubMed Web of Science ®Google Scholar
• Lokugamage N, Freiberg AN, Morrill JC, et al. Genetic subpopulations of Rift Valley Fever ZH548, MP-12 and recombinant MP-12 strains. J Virol. 2012;86:13566–13575.
   PubMed Web of Science ®Google Scholar
• Pittman PR, McClain D, Quinn X, et al. Safety and immunogenicity of a mutagenized, live attenuated Rift Valley fever vaccine, MP-12, in a phase 1 dose escalation and route comparison study in humans. Vaccine. 2016;34:424–429.
   PubMed Web of Science ®Google Scholar
• Pittman PR, Norris SL, Brown ES, et al. Rift Valley fever MP-12 vaccine phase 2 clinical trial: safety, immunogenicity, and genetic characterization of virus isolates. Vaccine. 2016;34:523–530.
   PubMed Web of Science ®Google Scholar
• Gardner CL, Ryman KD. Yellow fever: a reemerging threat. Clin Lab Med. 2010;30:237–260.
   PubMed Web of Science ®Google Scholar
• Monath TP. Stability of yellow fever vaccine. Dev Biol Stand. 1996;87:219–225.
   PubMedGoogle Scholar
• Cetron MS, Marfin AA, Julian KG, et al. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep. 2002;51:1–11.
   PubMedGoogle Scholar
• Tsai TF, Paul R, Lynberg MC, et al. Congenital yellow fever virus infection after immunization in pregnancy. J Infect Dis. 1993;168:1520–1523.
   PubMed Web of Science ®Google Scholar
• Nasidi A, Monath TP, Vandenberg J, et al. Yellow fever vaccination and pregnancy: a four-year prospective study. Trans R Soc Trop Med Hyg. 1993;87:337–339.
   PubMed Web of Science ®Google Scholar
• Rottingen JA, Gouglas D, Feinberg M, et al. New vaccines against epidemic infectious diseases. N Engl J Med. 2017;376:610–613.
   PubMed Web of Science ®Google Scholar
• Mehand MS, Al-Shorbaji F, Millett P, et al. The WHO R&D blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts. Antiviral Res. 2018;159:63–67.
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Vaccines for epidemic infections and the role of CEPI. Hum Vaccin Immunother. 2017;13:2755–2762.
   PubMed Web of Science ®Google Scholar
• McMillen CM, Arora N, Boyles DA, et al. Rift Valley fever virus induces fetal demise in Sprague-Dawley rats through direct placental infection. Sci Adv. 2018;4:eaau9812.
   PubMed Web of Science ®Google Scholar
• Mariner JC, House JA, Mebus CA, et al. Rinderpest eradication: appropriate technology and social innovations. Science. 2012;337:1309–1312.
   PubMed Web of Science ®Google Scholar
• Roeder P, Mariner J, Kock R. Rinderpest: the veterinary perspective on eradication. Philos Trans R Soc Lond B Biol Sci. 2013;368:20120139.
   PubMed Web of Science ®Google Scholar
• Ikegami T, Won S, Peters CJ, et al. Rescue of infectious rift valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene. J Virol. 2006;80:2933–2940.
   PubMed Web of Science ®Google Scholar
• Won S, Ikegami T, Peters CJ, et al. NSm and 78-kilodalton proteins of Rift Valley fever virus are nonessential for viral replication in cell culture. J Virol. 2006;80:8274–8278.
   PubMed Web of Science ®Google Scholar
• Won S, Ikegami T, Peters CJ, et al. NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis. J Virol. 2007;81:13335–13345.
   PubMed Web of Science ®Google Scholar
• Crabtree MB, Kent Crockett RJ, Bird BH, et al. Infection and transmission of Rift Valley fever viruses lacking the NSs and/or NSm genes in mosquitoes: potential role for NSm in mosquito infection. PLoS Negl Trop Dis. 2012;6:e1639.
   PubMed Web of Science ®Google Scholar
• Kading RC, Crabtree MB, Bird BH, et al. Deletion of the NSm virulence gene of Rift Valley fever virus inhibits virus replication in and dissemination from the midgut of Aedes aegypti mosquitoes. PLoS Negl Trop Dis. 2014;8:e2670.
   PubMed Web of Science ®Google Scholar
• Boumart Z, Daouam S, Bamouh Z, et al. Safety and immunogenicity of a live attenuated Rift Valley Fever recombinant arMP-12DeltaNSm21/384 vaccine candidate for sheep, goats and calves. Vaccine. 2019;37:1642–1650.
   PubMed Web of Science ®Google Scholar
• Nishiyama S, Slack OA, Lokugamage N, et al. Attenuation of pathogenic Rift Valley fever virus strain through the chimeric S-segment encoding sandfly fever phlebovirus NSs or a dominant-negative PKR. Virulence. 2016;7:871–881.
   PubMed Web of Science ®Google Scholar
• Ly HJ, Nishiyama S, Lokugamage N, et al. Attenuation and protective efficacy of Rift Valley fever phlebovirus rMP12-GM50 strain. Vaccine. 2017;35:6634–6642.
   PubMed Web of Science ®Google Scholar
• Food and Agriculture Organization of the United Nations (FAO): the last hurdles towards Rift Valley fever control. Proceeding of the Ad Hoc Workshop on the current state of Rift Valley fever vaccine and diagnostics development; 2014 Mar 5–7; Rome (Italy). FAO Animal Production and Health Report 2015; No.9.
   Google Scholar
• Bird BH, Albarino CG, Hartman AL, et al. Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. J Virol. 2008;82:2681–2691.
   PubMed Web of Science ®Google Scholar
• Bird BH, Maartens LH, Campbell S, et al. Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep. J Virol. 2011;85:12901–12909.
   PubMed Web of Science ®Google Scholar
• Smith DR, Johnston SC, Piper A, et al. Attenuation and efficacy of live-attenuated Rift Valley fever virus vaccine candidates in non-human primates. PLoS Negl Trop Dis. 2018;12:e0006474.
   PubMed Web of Science ®Google Scholar
• Wichgers Schreur PJ, Oreshkova N, Moormann RJ, et al. Creation of Rift Valley fever viruses with four-segmented genomes reveals flexibility in bunyavirus genome packaging. J Virol. 2014;88:10883–10893.
   PubMed Web of Science ®Google Scholar
• Wichgers Schreur PJ, van Keulen L, Kant J, et al. Four-segmented Rift Valley fever virus-based vaccines can be applied safely in ewes during pregnancy. Vaccine. 2017;35:3123–3128.
   PubMed Web of Science ®Google Scholar
• Faburay B, LaBeaud AD, McVey DS, et al. Current status of Rift Valley fever vaccine development. Vaccines (Basel). 2017;5. article number 29.
   Web of Science ®Google Scholar
• Indran SV, Ikegami T. Novel approaches to develop Rift Valley fever vaccines. Front Cell Infect Microbiol. 2012;2:131.
   PubMed Web of Science ®Google Scholar
• Okeke MI, Okoli AS, Diaz D, et al. Hazard characterization of modified vaccinia virus ankara vector: what are the knowledge gaps? Viruses. 2017;9:318.
   PubMed Web of Science ®Google Scholar
• Lopez-Gil E, Lorenzo G, Hevia E, et al. A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+-T cell activation and protects immune-competent mice against a lethal RVFV infection. PLoS Negl Trop Dis. 2013;7:e2309.
   PubMed Web of Science ®Google Scholar
• Alcock R, Cottingham MG, Rollier CS, et al. Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. Sci Transl Med. 2010;2:19ra2.
   Web of Science ®Google Scholar
• Lorenzo G, Lopez-Gil E, Ortego J, et al. Efficacy of different DNA and MVA prime-boost vaccination regimens against a Rift Valley fever virus (RVFV) challenge in sheep 12 weeks following vaccination. Vet Res. 2018;49:21.
   PubMed Web of Science ®Google Scholar
• Busquets N, Lorenzo G, Lopez-Gil E, et al. Efficacy assessment of an MVA vectored Rift Valley fever vaccine in lambs. Antiviral Res. 2014;108:165–172.
   PubMed Web of Science ®Google Scholar
• Alonso-Padilla J, Papp T, Kajan GL, et al. Development of novel adenoviral vectors to overcome challenges observed with HAdV-5-based constructs. Mol Ther. 2016;24:6–16.
   PubMed Web of Science ®Google Scholar
• Dicks MD, Spencer AJ, Edwards NJ, et al. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One. 2012;7:e40385.
   PubMed Web of Science ®Google Scholar
• Warimwe GM, Lorenzo G, Lopez-Gil E, et al. Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice. Virol J. 2013;10:349.
   PubMed Web of Science ®Google Scholar
• Warimwe GM, Gesharisha J, Carr BV, et al. chimpanzee adenovirus vaccine provides multispecies protection against Rift Valley fever. Sci Rep. 2016;6:20617.
   PubMed Web of Science ®Google Scholar
• Dulal P, Wright D, Ashfield R, et al. Potency of a thermostabilised chimpanzee adenovirus Rift Valley fever vaccine in cattle. Vaccine. 2016;34:2296–2298.
   PubMed Web of Science ®Google Scholar
• Gilbert SC, Warimwe GM. Rapid development of vaccines against emerging pathogens: the replication-deficient simian adenovirus platform technology. Vaccine. 2017;35:4461–4464.
   PubMed Web of Science ®Google Scholar
• Ikegami T, Makino S. Rift valley fever vaccines. Vaccine. 2009;27(Suppl 4):D69–72.
   PubMedGoogle Scholar